Department of Infectious Disease, Yokohama Municipal Citizen's Hospital, Japan.
Department of Infectious Disease, Yokohama Municipal Citizen's Hospital, Japan.
J Infect Chemother. 2021 Dec;27(12):1713-1715. doi: 10.1016/j.jiac.2021.08.008. Epub 2021 Aug 12.
Vaccination is one of the most important tools to control the COVID-19 pandemic. However, there is little information on the antibody response in humans after the COVID-19 vaccination.
This single-center, prospective study was conducted in Yokohama, Japan. We included health care workers who had received two doses of COVID-19 vaccination (BNT162b2) 21 days apart. We measured serum immunoglobulin G (IgG) to nucleoprotein and spike protein of SARS-CoV-2 with commercially available kits before and 7, 14, and 35 days after the first dose of vaccination.
A total of 104 workers participated in this study. Of these, 7 participants were seropositive with antibodies to spike protein at baseline and 4 of the 7 seropositive participants had COVID-19 history. The mean level of IgG to spike protein (QT) was 45.2, 1219, 2845, and 23489 AU/mL at baseline, on days 7, 14, and 35, respectively, although the values for nucleoprotein (NG) were 0.2, 0.21, 0.22, and 0.19 S/C, respectively. On day 7, QT in seropositive participants at baseline was elevated, whereas it was not elevated in seronegative participants at baseline until day 14.
QT was elevated over the cutoff in all the participants at day 35, but NG did not change between baseline and day 35.
接种疫苗是控制 COVID-19 大流行的最重要手段之一。然而,关于人类接种 COVID-19 疫苗后的抗体反应,信息很少。
这是一项在日本横滨进行的单中心、前瞻性研究。我们纳入了间隔 21 天接受两剂 COVID-19 疫苗(BNT162b2)的医护人员。我们在接种第一剂疫苗前、第 7、14 和 35 天,使用市售试剂盒检测血清中针对 SARS-CoV-2 核衣壳蛋白和刺突蛋白的免疫球蛋白 G(IgG)。
共有 104 名工作人员参与了这项研究。其中,7 名参与者在基线时就存在针对刺突蛋白的抗体,且 7 名抗体阳性者中有 4 人有 COVID-19 病史。在基线、第 7、14 和 35 天,针对刺突蛋白的 IgG(QT)水平分别为 45.2、1219、2845 和 23489 AU/mL,而针对核衣壳蛋白(NG)的水平分别为 0.2、0.21、0.22 和 0.19 S/C。在第 7 天,基线时抗体阳性的参与者的 QT 升高,而基线时抗体阴性的参与者直到第 14 天才升高。
在第 35 天,所有参与者的 QT 均超过截断值,但 NG 在基线和第 35 天之间没有变化。